Pharmacogenetics and pharmacogenomics is a field of research that studies how genetic or genomic variations among patients affect the efficacy or safety of particular drug treatment. It aims to discover genetic or genomic biomarkers that could drive stratified drug development by identifying patient subgroups most likely to respond. The discovery of clinically relevant biomarkers, or companion diagnostics, has revolutionized the practice of drug treatment, making tailored medicine for each patient possible. Therefore, the systematic application of pharmacogenomics in drug clinical trials or clinical case studies provides opportunities for screening biomarkers of individualized drug therapy. Furthermore, it will promote the drug-companion diagnostics co-development in the subsequent drug R&D and provide mechanistic insights into patient-specific factors that influence treatment responses, therefore paving the way to personalized medicine.
In addition to genomics, the other types of omics information can also contribute to variability in drug responses, such as epigenomics, transcriptomics, proteomics, and metabolomics. Rapid advances in multiomics technologies provide opportunities and challenges of integrating omics features from different molecular layers for personalized medicine. Integrating multiomics datasets will help determine the functional effects of genetic variations and their underlying mechanisms of action. Moreover, biomarkers of efficacy and safety can also be developed at the individual omics levels, combinatorial omics levels, and network levels. Therefore, "pharmacogenomics" will have evolved into "pharmaco-omics" to help us make better informed therapeutic decisions. However, many pitfalls ranging from data generation and analysis to data interpretation remain in the development of biomarkers for clinical applications. This Research Topic on "Pharmacogenetics and Pharmacogenomics" will report recent progress in addressing such technological challenges and practical examples of clinical relevance.
We welcome authors to contribute Review or Original Research articles focusing on current advances and future perspectives in multiomics approaches for personalized medicine. This Research Topic will provide new insights on the different aspects of "pharmaco-omics", including, but not limited to:
- Recent advances and remaining challenges of multiomics profiling technologies in data generation, data analysis, and data interpretation;
- Clinical cohorts or case studies exploring biomarkers of personalized drug therapy using multiomics technologies;
- Data mining for biomarkers of drug responses (efficacy and safety) using public multiomics datasets, and
- Computational tools or databases for better and more efficient reuse of public multiomics resources.
Pharmacogenetics and pharmacogenomics is a field of research that studies how genetic or genomic variations among patients affect the efficacy or safety of particular drug treatment. It aims to discover genetic or genomic biomarkers that could drive stratified drug development by identifying patient subgroups most likely to respond. The discovery of clinically relevant biomarkers, or companion diagnostics, has revolutionized the practice of drug treatment, making tailored medicine for each patient possible. Therefore, the systematic application of pharmacogenomics in drug clinical trials or clinical case studies provides opportunities for screening biomarkers of individualized drug therapy. Furthermore, it will promote the drug-companion diagnostics co-development in the subsequent drug R&D and provide mechanistic insights into patient-specific factors that influence treatment responses, therefore paving the way to personalized medicine.
In addition to genomics, the other types of omics information can also contribute to variability in drug responses, such as epigenomics, transcriptomics, proteomics, and metabolomics. Rapid advances in multiomics technologies provide opportunities and challenges of integrating omics features from different molecular layers for personalized medicine. Integrating multiomics datasets will help determine the functional effects of genetic variations and their underlying mechanisms of action. Moreover, biomarkers of efficacy and safety can also be developed at the individual omics levels, combinatorial omics levels, and network levels. Therefore, "pharmacogenomics" will have evolved into "pharmaco-omics" to help us make better informed therapeutic decisions. However, many pitfalls ranging from data generation and analysis to data interpretation remain in the development of biomarkers for clinical applications. This Research Topic on "Pharmacogenetics and Pharmacogenomics" will report recent progress in addressing such technological challenges and practical examples of clinical relevance.
We welcome authors to contribute Review or Original Research articles focusing on current advances and future perspectives in multiomics approaches for personalized medicine. This Research Topic will provide new insights on the different aspects of "pharmaco-omics", including, but not limited to:
- Recent advances and remaining challenges of multiomics profiling technologies in data generation, data analysis, and data interpretation;
- Clinical cohorts or case studies exploring biomarkers of personalized drug therapy using multiomics technologies;
- Data mining for biomarkers of drug responses (efficacy and safety) using public multiomics datasets, and
- Computational tools or databases for better and more efficient reuse of public multiomics resources.
